title: Serum and colostral antibody production in cows immunized with recombinant human tumor necrosis factor.
abstract: The use of hyper-immune bovine colostrum as a human therapeutic platform is an emerging technology with potential to deliver the efficacy of antibody therapeutics with the convenience and safety of oral or topical application. It is necessary to understand how the bovine immune system responds to immunization with foreign proteins, both in terms of the serum antibody response and the transfer of antigen-specific antibodies into the colostrum to enable efficient large-scale production of therapeutic antibodies. We have immunized 25 cows with recombinant human tumor necrosis factor (rhTNF) and measured the levels of rhTNF-specific antibodies in the serum and colostrum of these animals. We observed a decline of 84±9% in serum IgG1 concentrations in the final weeks of pregnancy that presumably reflects rapid transport of IgG1 into colostrum. The serum IgG2 levels remained constant, such that the serum IgG1 to IgG2 ratio was 1:20 at parturition. We observed substantial animal-to-animal variability in the levels of anti-rhTNF antibodies in both serum and colostrum samples. In particular, a subset of 4 cows had extraordinarily high colostral anti-rhTNF antibody production. Only a weak correlation was found between the peak serum anti-rhTNF activity and the colostral anti-rhTNF activity in these animals. The 4 cows with high colostral anti-rhTNF activities trended toward higher serum IgG1 loss relative to average colostral anti-rhTNF producers, but this difference was not statistically significant in this small sample. The high-anti-rhTNF-producing cows also exhibited a greater proportion of rhTNF-specific antibodies that bound to bovine IgG1- and IgG2-specific detection antibodies relative to the total anti-rhTNF immunoglobulin population. This finding suggests that the isotype distribution of the anti-rhTNF response is varied between individuals and genetic or environmental factors may increase the yield of antigen-specific colostral antibodies.
authors.affiliation: Avaxia Biologics Inc., 128 Spring Street, Lexington, MA 02124. Electronic address: rburton0830@gmail.com.
authors.forename: Randall
authors.initials: R
authors.lastname: Burton
authors.affiliation: Avaxia Biologics Inc., 128 Spring Street, Lexington, MA 02124.
authors.forename: Skaison
authors.initials: S
authors.lastname: Kim
authors.affiliation: Avaxia Biologics Inc., 128 Spring Street, Lexington, MA 02124.
authors.forename: Rutvij
authors.initials: R
authors.lastname: Patel
authors.affiliation: Avaxia Biologics Inc., 128 Spring Street, Lexington, MA 02124.
authors.forename: Michele
authors.initials: M
authors.lastname: Scola
authors.affiliation: Avaxia Biologics Inc., 128 Spring Street, Lexington, MA 02124.
authors.forename: Deborah
authors.initials: D
authors.lastname: Hartman
authors.affiliation: Avaxia Biologics Inc., 128 Spring Street, Lexington, MA 02124.
authors.forename: Daniel
authors.initials: D
authors.lastname: Tracey
authors.affiliation: Avaxia Biologics Inc., 128 Spring Street, Lexington, MA 02124.
authors.forename: Barbara S
authors.initials: BS
authors.lastname: Fox
mesh_terms: D000818:Animals; D002417:Cattle; D003126:Colostrum / Q000737:chemistry / Q000276:immunology*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007114:Immunization / Q000662:veterinary; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood*; D016014:Linear Models; D036801:Parturition / Q000276:immunology; D011247:Pregnancy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D007074:Immunoglobulin G; D011994:Recombinant Proteins; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha
keywords: antibody isotype; colostrogenesis; dairy cow; protein immunization